Stakeholder Insight: Hormonal Therapies in Breast Cancer

Introduction

Data from the ATAC trial provides strong evidence to support the superiority of anti-aromatase agents, specifically Arimidex, over tamoxifen. However anti-aromatase agents are significantly more expensive than generic tamoxifen. Utilizing data from Datamonitor’s Breast Cancer Insight study this report ascertains how receptive physicians are towards anti-aromatase agents, which they favor and why. 

Scope

An overview of the mechanisms of action of the hormonal drugs that are used in breast cancer, and their usage in different breast cancer populations 

An analysis of the infiltration of newer hormonal therapies, such as the aromatase inhibitors, into clinical practice 

Report Highlights

An analysis of Datamonitor’s Breast Cancer Insight survey results, which interviewed 580 leading breast cancer specialists across Europe, the US and Japan, in 2002, provides insight into the hormonal therapy of breast cancer patients. 

Reasons to Purchase

Plan new drug development to meet patient management requirements 

Explore the reasons, rational and emotional, behind cancer specialists' decisions 

Predict future trends and perception in the treatment of breast cancer patients 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a263